glp 1 agonist trials GLP-1 Receptor Agonists as Treatments for Type 2 Diabetes GLP-1 Receptor Agonists: An Alternative
Description
JAMA 330 , 17951797 (2023)
Only when Eli Lilly began testing dual GLP-1/GIP agonists did the picture change dramatically
The rise of the incretin therapies for obesity has attracted tremendous interest, both from drug developers and prospective patients (consumers)
However, given the novelty of this therapeutic approach, the available evidence may be influenced by publication bias and early optimism, and long-term mechanistic and clinical outcome data remain limited
The above studies confirm, to varying extent, the presence of higher RGC in patients exposed to GLP-1Ras
Renal Physiol
